L&T-TECHNOLOGY-SERVICES
1.2.2024 05:45:26 CET | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global digital engineering and R&D services company, supports Marelli, a leading mobility technology supplier to the automotive sector in redefining the landscape of automotive infotainment and information cluster design through the introduction of Marelli’s groundbreaking Digital Twin solutions. By harnessing the power of these innovative solutions, Marelli – supported by LTTS – has drastically streamlined automotive software development processes and reduced prototype costs, heralding a new era in the automotive industry for the development of Software Defined Vehicles (SDV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130254637/en/
Marelli's Digital Twin with the support of LTTS, offers a virtual replica of the entire car electric-electronic architecture - from information cluster to infotainment. (Graphic: Business Wire)
Built on Amazon Web Services (AWS), with the support of LTTS, Marelli's Digital Twin provides a virtual replica of the entire car electric-electronic architecture - from information clusters to infotainment, and from Zone Control Units to body. Leveraging Digital Cockpit that runs on the latest generation Snapdragon® Cockpit Platform from Qualcomm Technologies, Inc. and LTTS cloud-based virtualization solutions, Marelli's Digital Twin streamlines software development and prototype creation, cutting costs and accelerating timelines. This innovative solution is set to revolutionize the automotive industry, significantly reducing software development time by up to 70% and prototype costs by up to 30%.
The groundbreaking solution was showcased at the Consumer Electronics Show (CES) 2024, held in Las Vegas in January 2024.
“We are excited to join forces with LTTS in our ongoing efforts to enhance our Digital Twin,” expressed Roberto Secchi, Head of Software Platform and DevOps at Marelli’s Electronic Systems division. “Marelli has become a key player in the SDV arena, thanks to our dedicated investments and the exploration of various business prospects, all driven by our unwavering commitment to innovation. Leveraging LTTS’ capabilities will further boost our product portfolio, reinforcing Marelli as the premier technology partner for automotive companies.”
"We are thrilled to embark on a strategic collaboration with Marelli, leveraging the vast capabilities of software defined mobility, Digital Cockpit systems, connected cars to bolster Marelli's vision to revolutionize the future of mobility," said Abhishek Sinha, Chief Operating Officer and Board Member at L&T Technology Services. "This partnership is not only catalyzing unparalleled efficiencies in automotive software development but also spearheading the future of automotive infotainment through our groundbreaking digital twin offerings. Together, we are pioneering a new era of innovation, setting the stage for the next generation of mobility solutions."
Snapdragon is a trademark or registered trademarks of Qualcomm Incorporated.
Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,200 employees spread across 22 global design centers, 28 global sales offices and 105 innovation labs as of December 31, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130254637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom